On July 21, Novartis rose 3.76% in regular trading, trading at $154.1/share, with turnover of $79.53 million. The rally was driven by the company's Q2 earnings release that significantly exceeded market expectations.

Novartis reported Q2 adjusted earnings per share of $2.41, beating the consensus estimate of $2.13 by approximately 13%. Net sales came in at $14.408 billion, surpassing the expected $14.0 billion. Notably, Q1 results had disappointed due to generic competition against its blockbuster heart drug Entresto, but strong performance from next-generation oncology drugs successfully offset the generic impact this quarter, signaling a return to growth trajectory.

Additionally, Novartis CEO stated the company will continue pursuing acquisitions, particularly targeting deals under $2 billion while not ruling out larger transactions. The company also expects multiple key clinical data readouts in the second half, covering cardiology and multiple sclerosis, including del-desiran for muscular disease acquired through its $12 billion Avidity Biosciences deal.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)